Summary & Overview
CPT 81513: Molecular BV Assay on Vaginal Fluid with Algorithmic Interpretation
CPT code 81513 represents a molecular diagnostic assay that analyzes RNA markers from a vaginal fluid specimen for three bacterial species and applies an algorithm to report a positive or negative bacterial vaginosis (BV) result. This code captures both the technical amplification and the downstream algorithmic interpretation that yields a clinically actionable BV determination. As molecular and algorithm-based diagnostics expand, CPT code 81513 is significant for payers and laboratories because it combines laboratory analytics with an interpretive software component, affecting coverage, coding clarity, and reimbursement pathways.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical use, typical sites of service, and the role of algorithmic interpretation in BV testing. The report outlines benchmarks and coding context relevant to laboratories and billing teams, highlights payer considerations, and summarizes clinical implications for diagnosing bacterial vaginosis using nucleic acid amplification with automated interpretation. Data not available in the input is noted where applicable. The content is intended for national audiences involved in laboratory operations, medical billing, and payer policy.
Billing Code Overview
CPT code 81513 describes a laboratory procedure in which a lab analyst performs a quantitative real-time amplification assay of RNA markers on a vaginal fluid specimen for three specified bacterial species and uses an algorithmic analysis combining patient data and test results to report a positive or negative result for bacterial vaginosis (BV).
Service type: Laboratory diagnostic test with algorithmic/interpretive reporting.
Typical site of service: Clinical laboratory or hospital laboratory performing molecular diagnostic testing.
Clinical & Coding Specifications
Clinical Context
A reproductive-age female presents to an outpatient gynecology clinic with symptoms of abnormal vaginal discharge, vaginal odor, and mild vaginal irritation. The clinician performs a pelvic exam and collects a vaginal swab specimen. The specimen is sent to an independent or hospital clinical laboratory where a molecular assay is performed using quantitative real–time amplification of RNA markers for the three bacterial species specified in 81513. The laboratory analyst runs the technical component, integrates patient data (such as reported symptoms and specimen source) with the assay results using an algorithm, and reports a binary result: positive or negative for bacterial vaginosis (BV). Typical workflow steps include specimen collection at the clinic, specimen accessioning and testing in the lab, algorithmic interpretation, and reporting of results back to the ordering provider for clinical management decisions. Typical sites of service are outpatient clinic, ambulatory surgery center (if collection during other procedures), urgent care, and clinical laboratory (technical testing).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, Separately Identifiable Evaluation and Management Service by the Same Physician on the Day of a Procedure | Use when an E/M visit is performed and documented separately from specimen collection and ordering of . |